Friday, March 27, 2015

Drugs in Clinical Pipeline: Decernotinib

Decernotinib [(2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide] is an oral, selective Janus kinase 3 (JAK3) inhibitor. It is in Phase III  for the treatment of autoimmune and inflammatory diseases, including Rheumatoid Arthritis (RA).

In immune-mediated diseases, JAK3 is an essential component of the immune signaling cascade. This cascade ultimately contributes to abnormal immune response that results in chronic inflammation and, in the case of RA, irreversible damage to cartilage and bones.

IUPAC Name: (2R)-2-methyl-2-[[2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-N-(2,2,2-trifluoroethyl)butanamide
Common Name: VX-509; VRT-831509; Adelatinib
CAS No.: 944842-54-0
Originator: Vertex Pharmaceuticals